Obesity
+2
A Dose-Range Study of GSBR-1290 in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
About this trial
Last updated 7 months ago
Study ID
GSBR-1290-09
Status
Not yet recruiting
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18 to 79 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 7 months ago
What is this trial about?
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and
efficacy of various GSBR-1290 dose regimens compared with placebo in participants living
with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and
exercise, over a 36-week period.
What are the participation requirements?
Inclusion Criteria
- Signed informed consent
- BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity
Exclusion Criteria
- Previous documented diagnosis of diabetes mellitus
- Self-reported change in body weight >5% within 3 months before Screening
- Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed >1 year prior to screening)
- Use of medications intended to promote weight loss, within 6 months prior to Screening